Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.29 USD | +4.03% | +35.79% | +152.94% |
May. 06 | Oppenheimer Upgrades Chemomab Therapeutics to Outperform | MT |
Apr. 10 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 78.67 | 36.88 | 6.029 | 17.63 | - | - |
Enterprise Value (EV) 1 | 78.67 | 36.88 | 6.029 | 17.63 | 17.63 | 17.63 |
P/E ratio | -115 x | -26.4 x | -4.95 x | -43 x | -28.7 x | -28.7 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 11,401 | 11,526 | 11,821 | 14,219 | - | - |
Reference price 2 | 6.900 | 3.200 | 0.5100 | 1.290 | 1.290 | 1.290 |
Announcement Date | 3/9/22 | 2/21/23 | 3/7/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -12.37 | -28.53 | -25.46 | -16.2 | -22.59 | -26.04 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -12.48 | -28.18 | -24.22 | -15.82 | -27.25 | -33.18 |
Net income 1 | -5.951 | -12.48 | -27.65 | -24.22 | -15.82 | -22.29 | -26.04 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | - | -0.0600 | -0.1210 | -0.1030 | -0.0300 | -0.0450 | -0.0450 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/19/21 | 3/9/22 | 2/21/23 | 3/7/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -2.891 | -5.024 | -5.32 | -6.254 | -8.317 | -8.642 | -9.049 | -8.195 | -4.367 | -3.848 | -4.048 | -4.048 | -4.05 | -4.05 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -2.968 | -5.036 | -5.104 | -6.734 | -8.08 | -8.262 | -8.732 | -7.936 | -4.136 | -3.417 | -3.868 | -3.848 | -4.05 | -4.05 |
Net income 1 | -2.968 | -5.036 | -5.104 | -6.19 | -8.08 | -8.272 | -8.753 | -7.97 | -4.081 | -3.417 | -3.868 | -3.848 | -4.05 | -4.05 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.0130 | -0.0220 | -0.0220 | -0.0270 | -0.0350 | -0.0360 | -0.0400 | -0.0360 | -0.0170 | -0.0130 | -0.0140 | -0.0100 | -0.0100 | -0.0100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/12/21 | 3/9/22 | 5/12/22 | 8/12/22 | 11/10/22 | 2/21/23 | 5/11/23 | 8/14/23 | 11/9/23 | 3/7/24 | 5/9/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | 0.24 | 0.07 | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/19/21 | 3/9/22 | 2/21/23 | 3/7/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+152.94% | 17.63M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- CMMB Stock
- Financials Chemomab Therapeutics Ltd.